Skip to content

Released May 14, 2024, after the close

10-Q filed May 14, 2024, 44 days after period end · 0001390478-24-000010

Q1 2024 · 10-Q
Revenue—
Net Income-$9.57MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.21N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$9,645,000N/M
Operating Cash Flow-$10,761,000N/M

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue—$0.00$1.00M$5.70M
Net Income-$9.57M-$11.10M-$16.74M-$2.40M
EPS Diluted-$0.21-$0.47-$1.05-$0.16

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR